Celgene sales and marketing update

The U.K.’s NICE issued final draft guidance recommending against Abraxane nab-paclitaxel to treat pancreatic cancer in combination with gemcitabine. The agency said the cost of the drug is not justified by its “limited benefits compared to current treatments.” Earlier this year, the biotech appealed a final appraisal determination (FAD) recommending against the use of drug (see BioCentury, Feb. 2). ...